If the NFL Can Do It, So Can Scientists

In America's National Football League, a player gets full credit only for a so-called sack when he alone brings down the quarterback. In the world of US patents, a patent holder rakes in all the royalties if he or she is the sole name on the invention. If there's more than one name, the money is equally shared. It's called Laplace's Principle of Insufficient Reason: Without grounds for specifying unequal portions, the rational approach is to apportion equally. And it is, I'm convinced, the m

Written byCharles Romesburg
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

In America's National Football League, a player gets full credit only for a so-called sack when he alone brings down the quarterback. In the world of US patents, a patent holder rakes in all the royalties if he or she is the sole name on the invention. If there's more than one name, the money is equally shared.

It's called Laplace's Principle of Insufficient Reason: Without grounds for specifying unequal portions, the rational approach is to apportion equally. And it is, I'm convinced, the method by which scientists should calculate their citation numbers.

Too often, researchers imply they have X citations, when the proper implication is that they have made contributions to articles that have been cited X times. Consequently, those who judge applicants for research positions, or evaluate researchers for promotions and raises, would do well to apportion X as a step to sorting out whether each researcher's citation ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies